• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较经皮冠状动脉介入治疗的急性 ST 段抬高型心肌梗死患者冠状动脉内与静脉内替罗非班的疗效。

Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

机构信息

Department of Cardiology, The first hospital of QinHuangDao, QinHuangDao.

Department of Critical Care Medicine, People's Hospital of Yangjiang, Yangjiang.

出版信息

Coron Artery Dis. 2022 Nov 1;33(7):547-552. doi: 10.1097/MCA.0000000000001177. Epub 2022 Aug 9.

DOI:10.1097/MCA.0000000000001177
PMID:35942633
Abstract

OBJECTIVE

This study aimed to investigate the effect of intracoronary (IC) tirofiban compared to intravenously administered tirofiban in STEMI patients treated with PPCI.

METHODS

This study included 180 STEMI patients who were underwent PPCI. Patients were randomized into an IC group ( n = 90) and intravenous (IV) group ( n = 90). During the procedure, the both groups were administered IC or IV injections of tirofiban, respectively, followed by an IV infusion of tirofiban for 24 hours. Changes in TIMI flow grading, TMP grade 3, Sum-STR two hours after the operation, the number of thrombus aspirations during the operation, myocardial enzyme, inflammatory factors,cardiac functional parameters, MACE and bleeding were investigated.

RESULTS

Following treatment, TIMI flow grading and TMP grade 3 were improved in the IC tirofiban compared to the IV group ( P = 0.022 and P = 0.014, respectively). Additionally, the Sum-STR two hours after operation, the incidence of MACEs, levels of AST, CRP, ESR, and TNI in the IC group was improved, compared with the IV group (all P < 0.05). Furthermore. Cardiac function including CO and LVEF were significantly improved in the IC group 6 months after discharge.

CONCLUSION

This study found that IC administration of tirofiban in patients with STEMI who underwent PPCI improved TIMI, TMP flow and cardiac function 6 months after discharge, and reduced CRP, ESR, and TNI. However, the incidence of bleeding between the two groups was comparable. These findings suggest that IC administration should be applied in certain acute STEMI patients.

摘要

目的

本研究旨在探讨经皮冠状动脉介入治疗(PPCI)中冠状动脉内(IC)比伐芦定与静脉内给予比伐芦定对 ST 段抬高型心肌梗死(STEMI)患者的影响。

方法

本研究纳入了 180 例接受 PPCI 的 STEMI 患者。患者随机分为 IC 组(n = 90)和静脉(IV)组(n = 90)。在手术过程中,两组分别给予 IC 或 IV 比伐芦定注射,随后静脉输注比伐芦定 24 小时。观察手术前后 TIMI 血流分级、TMP 分级 3、术后 2 小时 Sum-STR、术中血栓抽吸次数、心肌酶、炎症因子、心功能参数、主要不良心血管事件(MACE)和出血情况的变化。

结果

治疗后,IC 比伐芦定组 TIMI 血流分级和 TMP 分级 3 较 IV 组改善(P = 0.022 和 P = 0.014)。此外,IC 组术后 2 小时 Sum-STR、MACE 发生率、AST、CRP、ESR 和 TNI 水平较 IV 组改善(均 P < 0.05)。此外,IC 组出院后 6 个月心脏功能包括 CO 和 LVEF 显著改善。

结论

本研究发现,PPCI 治疗的 STEMI 患者 IC 给予比伐芦定可改善 TIMI、TMP 血流和心脏功能 6 个月后,并降低 CRP、ESR 和 TNI。然而,两组间出血发生率相当。这些发现表明,IC 给药应应用于某些急性 STEMI 患者。

相似文献

1
Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.比较经皮冠状动脉介入治疗的急性 ST 段抬高型心肌梗死患者冠状动脉内与静脉内替罗非班的疗效。
Coron Artery Dis. 2022 Nov 1;33(7):547-552. doi: 10.1097/MCA.0000000000001177. Epub 2022 Aug 9.
2
Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention.糖尿病患者接受直接经皮冠状动脉介入治疗时冠脉内与静脉内大剂量推注替罗非班的临床结局
Cardiovasc J Afr. 2019;30(5):285-289. doi: 10.5830/CVJA-2019-027. Epub 2019 Jun 12.
3
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention.替罗非班对急性心肌梗死合并糖尿病患者行经皮冠状动脉介入治疗的影响。
Curr Vasc Pharmacol. 2024;22(1):41-49. doi: 10.2174/0115701611251882231012080210.
4
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗时的静脉内抗血小板治疗:来自 INVEST-STEMI 研究组的报告。
J Thromb Thrombolysis. 2024 Jun;57(5):757-766. doi: 10.1007/s11239-024-02970-7. Epub 2024 Apr 13.
5
Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.替罗非班冠脉内推注对行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者静脉上游治疗的有益影响:ICT-AMI 研究。
Int J Cardiol. 2013 May 25;165(3):437-43. doi: 10.1016/j.ijcard.2011.08.082. Epub 2011 Sep 21.
6
Effects of different doses of tirofiban combined with dual antiplatelet drugs on platelet indices, vascular endothelial function, and major adverse cardiovascular events in patients with acute ST-segment elevated myocardial infarction undergoing percutaneous coronary intervention.不同剂量替罗非班联合双联抗血小板药物对急性 ST 段抬高型心肌梗死患者行经皮冠状动脉介入治疗后血小板指标、血管内皮功能及主要不良心血管事件的影响。
Platelets. 2024 Dec;35(1):2402301. doi: 10.1080/09537104.2024.2402301. Epub 2024 Sep 26.
7
Intracoronary compared with intravenous bolus tirofiban on the microvascular obstruction in patients with STEMI undergoing PCI: a cardiac MR study.经皮冠状动脉介入治疗中冠状动脉内与静脉内推注替罗非班对 ST 段抬高型心肌梗死患者微血管阻塞的比较:一项心脏磁共振研究。
Int J Cardiovasc Imaging. 2020 Jun;36(6):1121-1132. doi: 10.1007/s10554-020-01800-0. Epub 2020 Feb 20.
8
Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.急性冠状动脉综合征经皮冠状动脉介入治疗期间冠状动脉内注射与静脉注射替罗非班的疗效和安全性:一项随机对照试验的荟萃分析
PLoS One. 2015 Jun 11;10(6):e0129718. doi: 10.1371/journal.pone.0129718. eCollection 2015.
9
[Efficacy comparison of combined intracoronary administration of high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention in patients with acute myocardial infarction].急性心肌梗死患者直接经皮冠状动脉介入治疗期间冠状动脉内联合应用大剂量腺苷与替罗非班对比冠状动脉内应用替罗非班的疗效比较
Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Oct;41(10):839-44.
10
Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction.通过血栓抽吸导管冠状动脉内注射固定剂量硝普钠预防急性心肌梗死直接经皮冠状动脉介入治疗后的无复流现象
Exp Ther Med. 2013 Aug;6(2):479-484. doi: 10.3892/etm.2013.1139. Epub 2013 Jun 4.

引用本文的文献

1
Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis.ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗期间冠状动脉内注射与静脉注射糖蛋白IIb/IIIa抑制剂的系统评价和荟萃分析
Thromb J. 2023 Jul 14;21(1):76. doi: 10.1186/s12959-023-00519-x.